Moreno-Manuel Andrea, Jantus-Lewintre Eloisa, Simões Ines, Aranda Fernando, Calabuig-Fariñas Silvia, Carreras Esther, Zúñiga Sheila, Saenger Yvonne, Rosell Rafael, Camps Carlos, Lozano Francisco, Sirera Rafael
Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain.
TRIAL Mixed Unit, Centro de Investigación Príncipe Felipe-Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain.
Transl Lung Cancer Res. 2020 Aug;9(4):1074-1083. doi: 10.21037/tlcr-19-445.
The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of and -two lymphocyte surface markers involved in the fine tuning of TCR signaling-as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC).
and gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC.
Patients with higher expression had significantly increased overall survival (OS, 49.63 . 99.90 months, P=0.013). expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher / ratio had significantly improved prognosis. Multivariate analysis established C expression as an independent prognostic biomarker for OS in early stages of NSCLC (HR=0.554; 95% CI, 0.360-0.853; P=0.007). Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both and expression¸ although expression alone did not reach significant prognostic value in our NSCLC training cohort.
Our data support further studies on and as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance.
肿瘤微环境中免疫监视的研究正在推动新生物标志物和治疗方法的发展。本研究聚焦于参与TCR信号微调的两种淋巴细胞表面标志物—— 和 的表达，将其作为可切除阶段非小细胞肺癌（NSCLC）的潜在预后生物标志物。
采用逆转录定量聚合酶链反应（RTqPCR）分析186对新鲜冷冻的可切除NSCLC肿瘤组织和正常组织样本中的 和 基因表达。
表达较高的患者总生存期（OS）显著延长（49.63 至99.90个月，P = 0.013）。 表达水平与CD4浸润及 表达水平相关，生存分析表明 / 比值较高的患者预后显著改善。多因素分析确定 表达是NSCLC早期OS的独立预后生物标志物（HR = 0.554；95% CI，0.360 - 0.853；P = 0.007）。对来自癌症基因组图谱（TCGA）数据库的NSCLC病例（n = 97）进行的进一步生存分析，证实了 和 的预后价值，尽管在我们的NSCLC训练队列中单独的 表达未达到显著的预后价值。
我们的数据支持进一步研究 和 作为可切除NSCLC及其他癌症类型（即黑色素瘤）的新型预后标志物，以及这些受体在免疫监视中的作用。
